Drug Safety Pharmacosurveillance: The Future is Now & Spelled G-e-n-o-m-I-c-s
|
|
- Julian Hamilton
- 6 years ago
- Views:
Transcription
1 Drug Safety Pharmacosurveillance: The Future is Now & Spelled G-e-n-o-m-I-c-s Dr. Bruce Carleton University of British Columbia Children s and Women s Health Centre of BC Child & Family Research Institute, Vancouver
2 Individual variability in drug response can have serious consequences Stevens-Johnson Syndrome (SJS) Adverse Drug Reaction
3 No one size fits all
4
5 WE CAN T TREAT CHILDREN LIKE ADULTS Increased Risk of Severe ADRs in Children >75% of approved drugs used in children are untested in pediatric populations Young children cannot evaluate or express their own response to medications Pediatric dosage forms not available Children metabolize drugs differently than adults
6 Variability in Drug Metabolites in Childhood Despite Administration of Equivalent Doses e.g. Valproic Acid Increased CYP2A6, CYP2C9 activity in children Increased formation of hepatotoxic metabolite in children
7 Developmental Modulation of Drug Metabolism in Children eg. Dextromethorphan (cough suppressant) % Metabolite Recovery 100% 80% 60% 40% 20% 0% 1 mo. 6 mo. CYP3A CYP2D6 1 yr 1 to 18 years? Age (years) adult 20 Leeder et al Drug Metab Rev 2000; 32(S2):281 Metabolized by CYP3A and CYP2D6 Relative contribution of CYP2D6 and CYP3A pathways changes during development Other CYP2D6 substrates: Codeine Acetaminophen Paxil
8 ADR Surveillance
9 Who Reports ADRs to Federal Regulators? Manufacturers ~190,000 Health Professionals and Consumers Physicians (700,000 in U.S.) Pharmacists (190,000 in U.S.) 13, % 2,083 15% 7,406 54% FDA 1997
10 How Big is the Problem of ADR Underreporting? It is estimated that 95% of ADRs are never reported Retrospective review of Toxic Epidermal Necrolysis cases in Canadian burn treatment centres from Jan Dec Only 25/674 (4%) of TEN cases were reported to CADRMP (Health Canada)
11 Passive Surveillance Increased reporting will improve understanding How much increase can reasonably be expected? What is the quality of the reports Are they missing critical data? Modification unlikely to achieve meaningful practice change in the prevention of serious ADRs
12 Active Surveillance ADR Surveillance clinicians who are trained in ADR recognition, evaluation and reporting Aim is to have full reporting All reports containing as much critical data as possible More standardized and thorough data collection processes
13 GATC: Genotypic Adjustment of Therapies in Childhood Project Leaders: Bruce Carleton & Michael Hayden
14 The GATC Project Hypothesis Genetic polymorphisms in drug biotransformation genes underlie a significant portion of concentration-dependent ADRs in children. Goal To develop genotype-based dosing guidelines to predict safety and avoid severe ADRs in children.
15 GATC Established Active ADR Surveillance Network at 8 sites across Canada Initiated DNA sample collection from ADR cases & controls Operational in 8 of Canada s major children s hospitals Serving 75% of all Canadian children Established community-based ADR Surveillance with the Canadian Pediatric Surveillance Program () Network of 2,300 pediatricians across Canada Funded by Health Canada Began ADR surveillance January 1, 2004 GATC VANCOUVER Children s &Women s Health Centre of B.C. Aug Surveillance Initiated GATC CALGARY Alberta Children s Hospital Feb Surveillance Initiated GATC WINNIPEG Winnipeg Children s Hospital Feb Surveillance Initiated LONDON Children s Hospital of Western Ontario Feb Surveillance Initiated GATC GATC GATC GATC TORONTO The Hospital for Sick Children Feb Surveillance Initiated OTTAWA Children s Hospital of Eastern Ontario Oct Surveillance Initiated GATC MONTREAL Sainte- Justine Children s Hospital Mar Surveillance Initiated HALIFAX IWK Grace Health Centre May 2006 Surveillance Initiated
16 GATC C17 Established Active ADR Surveillance Network at 8 sites across Canada Established community-based ADR Surveillance with the Canadian Pediatric Surveillance Program () Established a collaboration with the Canadian C-17 Oncology Network Network of all pediatric oncology departments across Canada C17 GATC C17 VANCOUVER Children s &Women s Health Centre of B.C. Aug Surveillance Initiated C17 GATC C17 CALGARY Alberta Children s Hospital Feb Surveillance Initiated C17 REGINA C17 GATC WINNIPEG Winnipeg Children s Hospital Feb Surveillance Initiated C17 LONDON C17 Children s Hospital of Western Ontario Feb Surveillance Initiated GATC C17 C17 GATC C17 GATC C17 GATC C17 TORONTO The Hospital for Sick Children Feb Surveillance Initiated OTTAWA Children s Hospital of Eastern Ontario Oct Surveillance Initiated GATC C17 MONTREAL Sainte- Justine Children s Hospital Mar Surveillance Initiated HALIFAX IWK Grace Health Centre May 2006 Surveillance Initiated
17 GATC Clinical Surveillance Network Identify children with ADRs Identify matched children on same medications, without ADRs Look for genetic variation in key drug ADME enzymes Informs new-drug development Develop new dosing guidelines Bedside-benchtop-bedside science
18 GATC GATC ADR Surveillance- Sample Collection Surveillance sites within hospitals/centres Inpatient wards Outpatient clinics Emergency departments Whenever possible, DNA samples is collected from biological parents of ADR patients
19 Established ADR Surveillance Networks across Canada Recruited over 8000 ADR cases and drugmatched controls Drug-Matched Controls Severe ADR Cases
20 the GATC network represents a unique contribution to the world serves as a model for studies worldwide. Arthur Holden, CEO, Serious Adverse Events Consortium (SAEC) The unique opportunities for ADR surveillance in Canada s national healthcare system have been seized upon with the GATC project. Giacomini et al, Nature, 2007 When good drugs go bad
21 GATC Genomic Analyses
22 Developed and tested ADME-tox SNP panel ADME-tox SNP Panel Raw Data (n = 480) Classification Genes AA AA Phase I Metabolism Phase II Metabolism Receptors/Drug Targets Transporters Transcription factors Ion Channels AA AB AB BB AA AB BB AB Call Rates >99% Reprod % Others 44 Total (3072 SNPs) 248 BB BB Running Whole Genome analyses when appropriate
23 Prioritized Focus on Three Serious ADRs: 1. Cisplatin-induced deafness 2. Anthracycline-induced cardiotoxicity 3. Codeine-induced infant mortality
24 Cisplatin Drug of choice for solid tumours including hepatoblastoma, ovarian, CNS, osteosarcoma, neuroblastoma, lung, bladder, head and neck tumors Commercialization assessment revealed 1,000,000 patients receive each year (N. America & Europe) Cisplatin-Induced Deafness ADR Causes permanent hearing loss 10-38% of patients Increased frequency and severity in children 28% of children 5-14 develop severe hearing loss 38% of children <5 yrs old develop severe hearing loss (Li et al, 2004) B.C. Children s Hospital: 37% of patients developed grade 3-4 deafness since 2005
25 Cisplatin-ADR Patient Recruitment Target : 150 cases, 150 controls Current: 75 cases, 79 controls Classification of Cisplatin ADR Cases and Controls Controls No hearing loss ADR Cases Grade 3 Hearing Loss: Severe Hearing Loss Requires intervention with hearing aid >20dB hearing loss at 2000 Hz Grade 4 Hearing Loss: Deafness Requires intervention with cochlear implant >40dB hearing loss at 1000Hz
26 Anthracyclines Administered to 60% all childhood cancer patients Adjuvant chemotherapy in breast cancer (50-90%, 22,000 patients/year in Canada) Commercialization assessment revealed 970,000 patients receive each year (N. America) Anthracycline-Induced Cardiotoxicity ADR Causes severe cardiotoxicity requiring ventricular assist device or heart transplant 10-30% of patients affected B.C. Children s Hospital: 17.9% develop cardiotoxicity (since 2006) Increased severity in children <15yr, esp. <4yr 8% of children end up on cardiac transplant list (BC Children s, 2008) Mortality rate: 61% (BC Cancer, 2005)
27 Anthracycline-ADR Patient Recruitment Target : 100 cases, 400 controls (July 15, 2008) Current: 78 cases, 313 drug-matched controls Classification of Anthracycline ADR Cases and Controls Controls No cardiotoxicity, shortening fraction >30% ADR Cases Grade 1 toxicity: Shortening fraction 24-30% or Resting ejection fraction 50-60% Grade 2 toxicity: Shortening fraction 15-24% or Resting ejection fraction 40-50% Grade 3 toxicity: Congestive heart failure Shortening fraction < 15% or Resting ejection fraction < 40% Grade 4 toxicity - Congestive heart failure requiring heart transplant or ventricular assist device Resting ejection fraction < 20%
28 Codeine-Induced Infant Mortality Initial Case Report: A new mother was given a standard dose of Tylenol #3 for obstetric pain relief Complained of significant drowsiness and constipation; dose reduced by 50% Infant showed poor feeding Infant died on day 13 due to respiratory failure Follow-up Analysis: Coroner brings case to GATC Maternal milk contained 87 ng/ml of morphine (10-20x expected) Infant s blood contained lethal levels of morphine (70 ng/ml)
29 Identified genetic variants associated with lethal reaction to codeine in newborns Mother s Genotype: CYP2D6 gene duplication UGT2B7*2/*2 Opioid activity in brain Outcome: Accumulation of morphine in breast milk Breast milk fed to infant Accumulation of morphine in infant caused CNS depression, respiratory failure, and death Infants do not express CYP2D6 and UGT2B7 and therefore do not metabolize morphine Codeine CYP3A4 Codeine 6-glucuronide Liver CYP2D6 Morphine UGT1A1 UGT2B7 UGT2B7 Morphine 3-glucuronide Morphine 6-glucuronide Kidney Koren et al, Lancet, 2006
30 Prior to Our Work The American Academy of Pediatrics and Drugs in Pregnancy in Lactation, the major reference guide to fetal and neonatal risk, list codeine as compatible with breastfeeding Briggs et al., 2005; Pediatrics, 2001
31 FDA Public Health Advisory Aug. 17, 2007
32 Estimated 1846 newborn infants are at risk for the codeine ADR each year in Canada (340,000 births, 73% breastfed, 52% mothers receive codeine post-childbirth,1.4% risk genotype) NEWS Codeine can turn toxic in nursing mothers May 11, 2006
33 GATC GATC GATC Overview DNA collected DNA genotyped Adverse Drug Reaction 1900 SNPs in 200 Candidate genes Integrate clinical & genotype data in association analyses Detailed Clinical Data Collected
34 II. ADR Biomarker Identification Candidate SNP Analysis Adverse Drug Reaction I. ADR Case Identification Novel Biomarker Discovery ADR Biomarker Validation SNP Genotyping Candidate Gene Sequencing ADR patient Controls Pharmacokinetic & proteomic studies Validated targets added to a lowcost diagnostic DNA chip Goal: Provide the scientific foundation to cost-effectively reduce severe childhood ADRs in Canada. III. ADR Biomarker Validation Pharmacokinetic Functional Validation Discovery of Novel ADR Biomarker Incorporation of validated ADR Biomarkers into Diagnostic Chip & SNP Platform Patient to receive drug X DNA Diagnostics ADR Screen Report Drug X: 10-fold increased risk of reaction Drug Y: 5-fold increased risk Drug Z: 20-fold increased risk
35 GATC Team Clinical Surveillance: Pharmacogenomics: Pharmacokinetics: Data Management: Health Economics: Bruce Carleton, UBC Gideon Koren, Univ of Toronto Stuart MacLeod, CFRI/UBC Michael Hayden, UBC Michael Phillips, Univ of Montréal Steven Leeder, Univ of Missouri Colin Ross, UBC Michael Rieder, UWO David Freeman, UWO Marie-Pierre Dube, Univ of Montréal Wyeth Wasserman, UBC Deborah Marshall, McMaster Kathryn Phillips, UCSF
36 What Differentiates Our Work Unique active surveillance network Drug-matched controls The Canadian Advantage National Health Care System Network embedded within the Health Care System Pragmatic value identified by stakeholders C17 Network will play a key role in advancing the safe care of patients Oncologists will significantly impact the care and treatment of patients Patients I support this research I ended up in ICU because of my heart BC Children s Hospital President..clear examples of therapeutic value Director, Emerg. Med., BC Children s:..will improve the safe use of drugs in children and adults with cancer Next: The Canadian Pharmacogenomic Network for Drug Safety
Colin Ross, PhD Centre for Molecular Medicine & Therapeutics Department of Medical Genetics University of British Columbia
Introduction to Pharmacogenomics for Clinicians: Pharmacogenomics of Adverse Drug Reactions Colin Ross, PhD Centre for Molecular Medicine & Therapeutics Department of Medical Genetics University of British
More informationPharmacogenetics of Codeine. Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA
Pharmacogenetics of Codeine Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA 1 Codeine Overview Naturally occurring opium alkaloid Demethylated to morphine for analgesic effect
More informationPharmacogenomic Prediction of Anthracyclineinduced Cardiotoxicity in Childhood Cancer Folefac Aminkeng The University of British Columbia
Pharmacogenomic Prediction of Anthracyclineinduced Cardiotoxicity in Childhood Cancer Folefac Aminkeng The University of British Columbia 1 Outline Background and Rationale Aminkeng F et al, Nature Genetics
More informationFrequently Asked Questions
Page 1 Frequently Asked Questions Codeine and all multiple-ingredient products containing codeine are restricted on the AHS Provincial Drug Formulary to patients 18 years of age and older. 1. What does
More informationData sharing in Canada through the COGR:
Data sharing in Canada through the COGR: a unified clinical genome database as a community resource for standardizing and sharing genetic interpretations Dr. Matthew Lebo, Kathleen-Rose Zakoor, Dr. Jordan
More informationTogether we ve achieved many successes. THE CH.I.L.D. FOUNDATION
Together we ve achieved many successes. THE CH.I.L.D. FOUNDATION Established 1995 Co-founders Grace McCarthy OC, OBC, Lindsay Gordon and Mary Parsons establish the Foundation for Children with Intestinal
More informationPersonalized Genomic Medicine: What is it? Why should I care? How can I use it?
Friday, October 17, 2014 Olli Lifelong Learning Health Education Series Lunch and Learn UNC-Asheville Campus Lynn G. Dressler, Dr.P.H. Director, Personalized Medicine Mission Health Fullerton Genetics
More informationGenomics (HMGP 7620) Pharmacogenomics.
Genomics (HMGP 7620) Pharmacogenomics http://unlockinglifescode.org/explore/genomic-medicine/pharmacogenomics Matthew Taylor MD PhD matthew.taylor@ucdenver.edu Variety is the Spice of Life Current Model:
More informationAnnex III. Amendments to relevant sections of the product information
Annex III Amendments to relevant sections of the product information Note: These amendments to the relevant sections of the Summary of Product Characteristics and Package Leaflet are the outcome of the
More informationFORENSIC SCIENCE NEWSLETTER Forensic Pathology and Neuropathology. William A. Cox, M.D., FCAP.
FORENSIC PATHOLOGY FORENSIC SCIENCE NEWSLETTER Forensic Pathology and Neuropathology William A. Cox, M.D., FCAP www.forensicjournals.com June 1, 2016 The Safety of Newborn Infants who are Breast Fed by
More informationMonique J. Roobol. Active Surveillance: update on Initiatives
Monique J. Roobol Associate professor Dept. of Urology Erasmus University Medical Center Rotterdam, the Netherlands Active Surveillance: update on Initiatives Overview Studies on Active Surveillance world
More informationNATIONAL SYNERGISTIC CORE RESOURCES. Kidney REsearch Scientist Core Education and National Training program (KRESCENT)
Strategy for Patient-Oriented Research Putting Patients First VISION Can-SOLVE CKD Network Vision: By 2020, every Canadian with, or at high risk for, chronic kidney (CKD) will receive the best recommended
More informationQuarter Performance Report
Canadian Cancer Clinical Trials Network Quarter Performance Report Quarter, FY 08/9 (Year 5): July Sept. 30, 08 Report Created: January 4, 09 Table of Contents Section A: Patient access and recruitment
More informationPEDIATRIC OTOLARYNGOLOGY FELLOWSHIP. B.C. Children s Hospital University of British Columbia Vancouver, B.C.
PEDIATRIC OTOLARYNGOLOGY FELLOWSHIP B.C. Children s Hospital University of British Columbia Vancouver, B.C. Program Director: Number of Positions: Dr. Neil K Chadha One per annum Next available Fellowship
More informationUpdate on Royal College Areas of Focused Competence (Diploma) Programs. Application Sponsor: National Body / Specialty Society
Update on Areas of Focused Competence (Diploma) AFC (Diploma) Program 1 Acute Care Point of Care Ultrasonography (Acute Care POCUS) Emergency Paediatric Emergency of Point-of-care Ultrasonography EM Fellowships
More informationTABLE D-1 POST-M.D. TRAINEES EXITING QUEBEC TRAINING PROGRAMS IN JULY, 2014 AT THE COMPLETION OF POST-M.D. TRAINING
TABLE D-1 Family Medicine Emergency Medicine (CFPC) Care of the Elderly (CFPC) Enhanced Skills: Fam. Med. Training FAMILY MEDICINE SUBTOTAL Anesthesiology Critical Care (Anes.) Public Health and Preventive
More informationPOST-M.D. TRAINEES EXITING ALBERTA TRAINING PROGRAMS IN JULY, 2015 AT THE COMPLETION OF POST-M.D
TABLE D-1 Family Medicine Emergency Medicine (CFPC) Care of the Elderly (CFPC) Enhanced Skills: Fam. Med. Training FAMILY MEDICINE SUBTOTAL Anesthesiology Public Health and Preventive Medicine Dermatology
More informationGeographic Location, Field of Post-M.D. Training
TABLE D-1 Family Medicine Emergency Medicine (CFPC) Care of the Elderly (CFPC) Enhanced Skills: Fam. Med. Training FAMILY MEDICINE SUBTOTAL Anesthesiology Critical Care (Anes.) Public Health and Preventive
More information2016 ADHD Conference Speaker Biographies
2016 ADHD Conference Speaker Biographies Dr. Rosemary Tannock, PhD Rosemary Tannock is now Professor Emerita at the University of Toronto and continues as a Senior Scientist at the Hospital for Sick Children
More informationPEDIATRIC OTOLARYNGOLOGY-HEAD AND NECK SURGERY CLINICAL FELLOWSHIP. B.C. Children s Hospital University of British Columbia Vancouver, B.C.
PEDIATRIC OTOLARYNGOLOGY-HEAD AND NECK SURGERY CLINICAL FELLOWSHIP B.C. Children s Hospital University of British Columbia Vancouver, B.C. Program Director: Number of Positions: Dr. Neil K Chadha One per
More informationHow long does codeine stay in breast milk
How long does codeine stay in breast milk 2-4-2009 How long does t3's with codeine stay in my system after withholding breast feeding and infants exposed to codeine in milk. Once you have decided to stop
More informationPOLICY and PROCEDURE
Misericordia Community Hospital Administration of Intravenous FentaNYL During Labour POLICY and PROCEDURE Labour and Delivery Manual Original Date Revised Date Approved by: Director, Women s Health, Covenant
More informationGeographic Location, Field of Post-M.D. Training
TABLE D-1 Family Medicine Emergency Medicine (CFPC) Care of the Elderly (CFPC) Enhanced Skills: Other Fam. Med. Training FAMILY MEDICINE SUBTOTAL Anesthesiology Critical Care (Anes.) Public Health and
More informationUpdate on Royal College Areas of Focused Competence (Diploma) Programs. Application Sponsor: National Body / Specialty Society
Update on Areas of Focused Competence (Diploma) AFC (Diploma) Program 1 Acute Care Point of Care Ultrasonography (Acute Care POCUS) Emergency Paediatric Emergency of Point-of-care Ultrasonography EM Fellowships
More informationSummary of the risk management plan (RMP) for Zykadia (ceritinib)
EMA/154751/2015 Summary of the risk management plan (RMP) for Zykadia (ceritinib) This is a summary of the risk management plan (RMP) for Zykadia, which details the measures to be taken in order to ensure
More informationHIV Testing. Susan Tusher, LMSW Program Coordinator The Kansas AIDS Education and Training Center
HIV Testing Susan Tusher, LMSW Program Coordinator The Kansas AIDS Education and Training Center The Number of Persons in the US Living with HIV Continues to Increase Over 1 Million people are estimated
More informationMarlene Bagatto. The University of Western Ontario, London, Canada. Sound Foundations 2010, Chicago, USA
Marlene Bagatto The University of Western Ontario, London, Canada Sound Foundations 2010, Chicago, USA Acknowledgements Funding Sources: Canadian Institutes of Health Research Vanier Canada Graduate Scholarship
More informationLinking Pharmacovigilance and Pharmacogenomics
Linking Pharmacovigilance and Pharmacogenomics Dr. Bruce Carleton Professor of Pediatrics, Pharmaceutical Sciences, Population & Public Health, Medical Genetics, University of British Columbia Director,
More informationFDA Approves ABRAXANE for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
October 12, 2012 FDA Approves ABRAXANE for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Approval Based on Significantly Improved Overall Response Rates in all Patients Regardless of
More informationEstimating organ donor potential: a comparable tool to track performance, identify gaps and help save lives
Estimating organ donor potential: a comparable tool to track performance, identify gaps and help save lives Presented by: Christina Lawand, Senior Researcher Sheril Perry, Project Lead Health System Analysis
More informationNATIONAL HOUSEHOLD SURVEY BRIEF FERTILITY RATES OF OTTAWA'S JEWISH COMMUNITY
NATIONAL HOUSEHOLD SURVEY BRIEF FERTILITY RATES OF OTTAWA'S JEWISH COMMUNITY BY CHARLES SHAHAR APRIL 2015 2011 National Household Survey Brief Fertility Rates of Ottawa's Jewish Community This brief examines
More informationThe safety concerns defined with the reference product apply to Buprenorphine-Naloxone 2/0.5 mg, 8/2 mg, sublingual tablets.
These products are indicated in the substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: October 15, 2018 Related Policies: 2.04.38 Cytochrome P450 Genotype-Guided Treatment Strategy Genotype-Guided Tamoxifen Treatment Description Tamoxifen is prescribed
More informationPROVINCIAL LEAD AND LHIN LEADER BIOS
PROVINCIAL LEAD AND LHIN LEADER BIOS May 4, 2006 Dr. Bernard Lawless, Provincial Lead Dr. Bernard Lawless completed a residency in general surgery at the University of Western Ontario (UWO) and then did
More informationSpecial pediatric considerations are noted when applicable, otherwise adult provisions apply.
DRUG NAME: Lomustine SYNONYM(S): CCNU 1 COMMON TRADE NAME(S): CeeNU CLASSIFICATION: alkylating agent Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM
More informationPRODUCT INFORMATION CODAPANE XTRA Paracetamol 500 mg and Codeine Phosphate 15 mg Tablets
PRODUCT INFORMATION CODAPANE XTRA Paracetamol 500 mg and Codeine Phosphate 15 mg Tablets NAME OF THE MEDICINE Active Ingredients: Paracetamol and Codeine Phosphate Paracetamol: Molecular Formula: C 8 H
More informationPAIN MEDICATION DNA INSIGHT
Test Results Reviewed & Approved by: Laboratory Director, Nilesh Dharajiya, M.D. PAIN MEDICATION DNA INSIGHT PERSONAL DETAILS DOB Jan 1, 19XX ETHNICITY Caucasian ORDERING HEALTHCARE PROESSIONAL Nilesh
More informationALBERTA PRINCIPAL INVESTIGATORS
ALBERTA PRINCIPAL INVESTIGATORS Dr. Gregory Cairncross is Head of the Department of Clinical Neurosciences at the University of Calgary and holder of the Alberta Cancer Foundation Chair in Brain Tumor
More informationHow much codeine can you drink
Search... How much codeine can you drink 23-2-2018 There are other effects of Purple Drank abuse that are an overdose of codeine when abusing Purple Drank, rehab program can be the last one you ever. GO
More informationPARACOD Tablets (Paracetamol + Codeine phosphate)
Published on: 22 Sep 2014 PARACOD Tablets (Paracetamol + Codeine phosphate) Composition PARACOD Tablets Each effervescent tablet contains: Paracetamol IP...650 mg Codeine Phosphate IP... 30 mg Dosage Form/s
More informationBACKGROUNDER. Results of the 2017 Large-Scale Applied Research Project Competition: Genomics and Precision Health
January 23, 2018 BACKGROUNDER Results of the 2017 Large-Scale Applied Research Project Competition: Genomics and Precision Health Genome Canada, in collaboration with the Canadian Institutes of Health
More informationPEDIATRIC PREVENTIVE HEALTH GUIDELINES
PEDIATRIC PREVENTIVE HEALTH GUIDELINES Each child and family is unique; therefore, these Guidelines for Preventive Pediatric Health Care are designed for the care of children who are receiving competent
More informationImplementing Rapid Response Teams (RRT) National Call September 13, 2007
Implementing Rapid Response Teams (RRT) National Call September 13, 2007 Purpose By the end of this call, participants will have: Heard successes and learnings from Improvement Teams Updated information
More informationHow to Evaluate the Heart of Elderly Patients
How to Evaluate the Heart of Elderly Patients Special considerations regarding cardiotoxicity Michael S. Ewer MD The University of Texas M. D. Anderson Cancer Center Why Discuss Cardiac Disease and Cancer
More informationHealth Interventions in Ambulatory Cancer Care Centres DRAFT. Objectives. Methods
ENVIRONMENTAL SCAN Health Interventions in Ambulatory Cancer Care Centres Context Cancer, a complex, chronic condition, will affect an estimated two in five Canadians in their lifetime. 1 Cancer requires
More informationThe Terry Fox Pan-Canadian Enhanced Pancreatic Cancer Profiling for Individualized Care (EPPIC) Project 19 Sep :00am-5:30pm
TFRI Pancreatic Cancer Workshop Project Name: Date: The Terry Fox Pan-Canadian Enhanced Pancreatic Cancer Profiling for Individualized Care (EPPIC) Project 19 Sep 2015 9:00am-5:30pm Location: Sheraton
More informationNATIONAL HOUSEHOLD SURVEY BRIEF FERTILITY RATES OF TORONTO'S JEWISH COMMUNITY
NATIONAL HOUSEHOLD SURVEY BRIEF FERTILITY RATES OF TORONTO'S JEWISH COMMUNITY BY CHARLES SHAHAR APRIL 2015 2011 National Household Survey Brief Fertility Rates of Toronto's Jewish Community This brief
More informationMarijuana Use During Pregnancy and Breastfeeding Findings Summary
The Colorado Department of Public Health and Environment (CDPHE) was assigned the responsibility to appoint a panel of health care professionals with expertise in cannabinoid physiology to monitor the
More informationCardiovascular outcomes in survivors of childhood cancer
Cardiovascular outcomes in survivors of childhood cancer Paul Nathan MD, MSc Director, AfterCare Program Division of Haematology/Oncology The Hospital for Sick Children, Toronto Conflicts Nothing to declare
More informationThe Deciphering Development Disorders (DDD) project: What a genomic approach can achieve
The Deciphering Development Disorders (DDD) project: What a genomic approach can achieve RCP ADVANCED MEDICINE, LONDON FEB 5 TH 2018 HELEN FIRTH DM FRCP DCH, SANGER INSTITUTE 3,000,000,000 bases in each
More informationShelly A McNeil, MD on behalf of the SOS Network of the Canadian Immunization Research Network (CIRN) CIC 2016 Dec 6-8, 2016 Ottawa, ON
Resource Utilization and Cost of Laboratory Confirmed Influenza Requiring Hospitalization in Canadian Adults A Study from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research
More informationTABLE D-1 POST-M.D. TRAINEES EXITING ONTARIO TRAINING PROGRAMS IN JULY, 2013 AT THE COMPLETION OF POST-M.D. TRAINING
TABLE D-1 Family Medicine Emergency Medicine (CFPC) Care of the Elderly (CFPC) Enhanced Skills: Other Fam. Med. Training FAMILY MEDICINE SUBTOTAL Palliative Medicine TRAINING FOLLOWING FAMILY MEDICINE
More informationAcademic Critical Care Medicine. University of Alberta
Academic Critical Care Medicine University of Alberta Established Specialty Critical Care Medicine now embodies a unique body of knowledge of the epidemiology, assessment, treatment and outcomes of critical
More informationMISCELLANEOUS AGENTS - ALPHA-AGONISTS
Documentation A. FDA Approved Indications ADHD (Clonidine, Guanfacine) Documentation B. Non-FDA approved, commonly used psychiatric indications 1. Alcohol and opiate dependence 2. Opioid withdrawal 3.
More informationAntifungal Susceptibility of Aspergillus Isolates from the Respiratory Tract of Patients in Canadian Hospitals: Results of the CANWARD 2016 Study.
1 Antifungal Susceptibility of Aspergillus Isolates from the Respiratory Tract of Patients in Canadian Hospitals: Results of the CANWARD 2016 Study. J. FULLER 1,3, A. BULL 2, S. SHOKOPLES 2, T.C. DINGLE
More informationSummary of the risk management plan (RMP) for Tagrisso (osimertinib)
EMA/2497/2016 Summary of the risk management plan (RMP) for Tagrisso (osimertinib) This is a summary of the risk management plan (RMP) for Tagrisso, which details the measures to be taken in order to ensure
More informationCardiotoxic Effects of Chemotherapy on Pediatric and Adult Survivors of Cancer
Cardiotoxic Effects of Chemotherapy on Pediatric and Adult Survivors of Cancer Dr. Chris Fryer, Pediatric Oncologist, BC Children s Hospital Dr. Sean Virani, Founding Director, UBC Cardiovascular Oncology
More information3. Describe how variants in the CYP2C19 gene impact Plavix metabolism. 4. Compare molecular genetic technologies for pharmacogenomics testing
UP! UNDERSTANDING PHARMACOGENOMICS (PGX) Robert Pyatt Ph.D., Director Sanford Medical Genetics and Genomics Laboratories and Associate Professor, Dept of Internal Medicine, University of South Dakota April
More informationWARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,
Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901 Tel 908-673-9000 Fax 908-673-9001 October 2012 NEW Indication Announcement for ABRAXANE for Injectable Suspension (paclitaxel protein-bound
More informationOn Parents, Children And the Drugs Between Them
On Parents, Children And the Drugs Between Them Memories from Toronto Gal Neuman Clinical Pharmacology & Toxicology Pediatric Medicine Maccabi Health Care Services Former staff, Israeli Poison Information
More informationUpdate on Royal College Areas of Focused Competence (Diploma) Programs. Application Sponsor: National Body / Specialty Society
Update on Areas of Focused Competence (Diploma) AFC (Diploma) Program 1 Acute Care Point of Care Ultrasonography (Acute Care POCUS) Emergency Medicine Paediatric Emergency Medicine Canadian of Point-of-care
More informationWe asked, you answered
We asked, you answered an innovative method to sourcing answers to pressing health policy and health care questions CAHSPR 2016 Panel Discussion Canada Health Infoway 2016 1 Our Panel Erika Yates Senior
More informationObjectives Making CYP450, Drug Interactions, & Pharmacogenetics Easy
Objectives Making, Drug Interactions, & Pharmacogenetics Easy Anthony J. Busti, MD, PharmD, FNLA, FAHA Describe the differences between phase I and phase II metabolic pathways. Identify the most common
More informationImmodium / loprarmide
Immodium / loprarmide IMODIUM (loperamide hydrochloride) is indicated for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease.
More informationThe Technical Aspects of Pathogen Testing in Canada. Nancy Angus Canadian Blood Services Director, Testing
PERMISSON TO USE: Please note that, by making their presentations available on-line, primary authors have agreed to share their presentations. However, should you want to use some of the data or slides
More informationHealth Interventions in Ambulatory Cancer Care Centres
ENVIRONMENTAL SCAN Health Interventions in Ambulatory Cancer Care Centres Context Cancer a complex, chronic condition will affect an estimated two in five Canadians in their lifetime. 1 Cancer requires
More informationDemystifying Pharmacogenetics: its evolution and challenges. June 15, 2016
Demystifying Pharmacogenetics: its evolution and challenges June 15, 2016 Welcome! Dr. Brendan Byrne Chief Innovation Officer, TELUS Health Karen Kesteris Director, Product Management, TELUS Health 2 Today
More informationOAA Survey 156: Current prescribing practices for post-operative analgesia following emergency and elective LSCS
OAA Survey 56: Current prescribing practices for post-operative analgesia following emergency and elective LSCS Janis M Ferns, Jennifer Lambert, Dharshini Radhakrishnan 2. Specialty Trainee, Barts and
More informationigh-sensitivity Cardiac Troponin - A Canadian Viewpoint from CIHR funded studies Friday May 30, 2014
8:50-9:00 Welcome and Introduction Juravinski Cancer Center Lecture Theatre (4 th floor) 699 Concession St. Hamilton, ON L8V 5C2 Introduction to High-Sensitivity Cardiac Troponin Current State 9:00-9:45
More informationQuarter Performance Report
Canadian Cancer Clinical Trials Network Quarter Performance Report Quarter 07/8: April June 30, 07 Report Created: Sept 8, 07 Table of Contents Section A: Progress at Adult Network Sites... Section B:
More information2018 THERAPEUTICS UPDATE
The Canadian Society of Pharmacology and Therapeutics 2018 THERAPEUTICS UPDATE Course Overview This one-day course on May 22, 2018 will explore emerging areas of interest in drug therapy and drug safety.
More informationOpioids in Breast Milk: Pharmacokinetic Principles and Clinical Implications
Supplement Article Opioids in Breast Milk: Pharmacokinetic Principles and Clinical Implications The Journal of Clinical Pharmacology 2018, 58(S10) S151 S163 C 2018, The American College of Clinical Pharmacology
More informationCity of Vancouver s Response to the Opioid Crisis Fire Chief Darrell Reid Vancouver Fire & Rescue Services (VF&RS)
City of Vancouver s Response to the Opioid Crisis Fire Chief Darrell Reid Vancouver Fire & Rescue Services (VF&RS) Vancouver Vancouver Fire Rescue Services Opioid Crisis Background Crisis Overview April
More informationDaniel S. Sitar, BScPharm, PhD, FCP Professor Emeritus University of Manitoba Editor: Journal of Clinical Pharmacology
March 8, 2011 Daniel S. Sitar, BScPharm, PhD, FCP Email: sitar@cc.umanitoba.ca Professor Emeritus University of Manitoba Editor: Journal of Clinical Pharmacology DEFINITIONS Pain: The unpleasant sensory
More informationAssessment of G8 Commitments on Maternal, Newborn and Child Health
Assessment of G8 Commitments on Maternal, Newborn and Child Health Robin Lennox Researcher, G8 Research Group June 13, 2010 In January 2010, Canadian prime minister Stephen Harper announced that maternal,
More informationRydapt. Summary of the Risk Management Plan (RMP) for Rydapt (midostaurin)
Regulatory Affairs Rydapt 25 mg soft capsules Summary of the Risk Management Plan (RMP) for Rydapt (midostaurin) Document version: 01 Document status: Document Date: Final 02-June-2017 1 of 6 Summary of
More informationPoison Control Centres
Poison Control Centres Monica Durigon Field Epidemiologist Public Health Agency of Canada Joanne Stares Public Health Officer Public Health Agency of Canada Placement site: BC Centre for Disease Control
More informationPharmacovigilance Paediatric Perspective
Pharmacovigilance Paediatric Perspective To give insight into the specifics of reviewing pharmacovigilance reports for children Kristina Star, RN, PhD May 30, 2013 Patient harm Medicines can cause patient
More informationThe G8 Dementia Summit: A Giant Step Forward for Dementia
The G8 Dementia Summit: A Giant Step Forward for Dementia January 28, 2014 Mimi Lowi-Young, M.H.A, Dip Bus. Admin., FACHE, FCCHL Chief Executive Officer, Alzheimer Society of Canada Overview 1. Background
More informationCanadian Health Care Systems
Vaccine Decisions: Policy Making and Priority Setting in Canadian Health Care Systems Charlotte Moore Hepburn, MD, FRCPC, FAAP Lead, Child Health Policy Initiative Faculty Pediatrician, Division of Pediatric
More informationCardio oncology Double Jeopardy
Cardio oncology Double Jeopardy Edie Pituskin RN MN (NP Adult) PhD NP Forum for Nursing and Allied Health, April 10, 2015 Aims Describe the double jeopardy faced by cancer patients Discuss issues in detection
More informationOtotoxicity Monitoring: The M. D. Anderson Experience. James H. Hall, Jr., M.A., CCC-A Hilary H. Arnaud, Au.D., CCC-A
Ototoxicity Monitoring: The M. D. Anderson Experience James H. Hall, Jr., M.A., CCC-A Hilary H. Arnaud, Au.D., CCC-A Objectives Overview and presentation of cancer in adult and pediatric patients Discuss
More informationDr. Manish Sadarangani
Clinical features and outcomes of invasive pneumococcal disease in Canada between 1991 and 2015 M Sadarangani, SK Morris, JD Kellner, N Le Saux, J Embree, OG Vanderkooi, I Martin, W Demczuk, GJ Tyrrell,
More information1. To provide an update of the diagnosis, pathophysiology, outcome, screening and management of pregnancies complicated by IUGR.
FETAL GROWTH 2016 Thursday November 17 Saturday November 19, 2016 Salter Auditorium, Hospital for Sick Children Sadowski Auditorium, Mount Sinai Hospital www.fetalgrowth2016.ca Dear Colleagues: We are
More informationMedical Policy Title GENOTYPING URIDINE DIPHOSPHATE GLYCURONOSYLTRANSFERASE (UGT1A1) FOR PATIENTS TREATED WITH IRINOTECAN Policy Number 2.02.
Page: 1 of 5 MEDICAL POLICY MEDICAL POLICY DETAILS Medical Policy Title GENOTYPING URIDINE DIPHOSPHATE GLYCURONOSYLTRANSFERASE (UGT1A1) FOR Policy Number 2.02.34 Category Laboratory Tests Effective Date
More informationEvaluation of Cabergoline for Lactation Suppression in Women Living with HIV
Evaluation of Cabergoline for Lactation Suppression in Women Living with HIV M. Roy, R. Thibaudeau, E. Ferreira, N. Sheehan, J. Autmizguine, C. Elwood, D. Money, K. Tulloch, I. Boucoiran 7 TH INTERNATIONAL
More informationProduct Labeling to Communicate Benefits and Risks of Treatment for Opioid Use Disorder in Pregnant Women. Hendrée E. Jones, PhD
1 The National Academies of Sciences, Engineering and Medicine Regulatory Strategies of address prescription opioidrelated harms 4 th of November, 2016 Washington DC Product Labeling to Communicate Benefits
More informationNeonatal Abstinence Syndrome Questions & Answers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012)
Neonatal bstinence Syndrome Questions & nswers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012) For more information and to download a copy of the NS Clinical Practice Guidelines, please visit
More informationMedical Late Effects of Childhood Cancer
Medical Late Effects of Childhood Cancer Robert Goldsby Associate Professor of Clinical Pediatric UCSF Late Mortality in 5+ Year Survivors 1.00 US Female US Male Survival function estimate 0.70 0.75 0.80
More informationCanadian Immunization Conference 2018 Dec 4
Enveloped Virus-Like Particle (evlp) Cytomegalovirus (CMV) Vaccine is immunogenic and safe: preliminary results of a First-in-Humans Canadian Immunization Network (CIRN) Clinical Trials Network (CTN) -
More informationPediatric Drug Development Current Challenges
Pediatric Drug Development Current Challenges Robert Ward, MD, FAAP, FCP Professor Emeritus, Pediatrics Founder Univ Utah Pediatric Pharmacology Program Former Attending Neonatologist University of Utah
More informationMarlene Bagatto The University of Western Ontario, London, Canada. European Pediatric Amplification Conference Istanbul, Turkey November 15, 2011
Marlene Bagatto The University of Western Ontario, London, Canada European Pediatric Amplification Conference Istanbul, Turkey November 15, 2011 Intervention for Childhood Hearing Loss Access to early
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. SYLVANT pronounced SILL-vant siltuximab for injection
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr SYLVANT pronounced SILL-vant siltuximab for injection Read this carefully before you start taking SYLVANT and each
More informationAssisted Reproductive Technologies
Assisted Reproductive Technologies ADDENDUM TO THE STEP REPORT August, 26 Submitted to: The Alberta Health Technologies Decision Process Research & Innovation Branch Strategic Planning & Policy Development
More informationGenetic Screening for ADR
Genetic Screening for ADR Mahidol University Faculty of Medicine Siriraj Hospital Manop Pithukpakorn, MD Division of Medical Genetics Department of Medicine concentration Drug level over time toxic optimum
More informationTiming of vaccination campaigns against pandemic influenza in a population dynamical model of Vancouver, Canada
Timing of vaccination campaigns against pandemic influenza in a population dynamical model of Vancouver, Canada Jessica M. Conway 1,2, Rafael Meza 2, Bahman Davoudi-Dehagi 2, Ashleigh Tuite 3, Babak Pourbohloul
More informationAre health care systems ready to deliver pharmacogenetics as standard of care? Predicting the needs and setting the strategies
Are health care systems ready to deliver pharmacogenetics as standard of care? Predicting the needs and setting the strategies David Gurwitz Sackler Faculty of Medicine, Tel-Aviv University, Israel OECD,
More informationHighly Sensitized Patient Registry: Update and Successes
Highly Sensitized Patient Registry: Update and Successes Dr. Olwyn Johnston Medical Director Kidney and Pancreas Transplant Program Vancouver General Hospital Conflict of Interest Transplant Nephrologist
More informationClinical Management of Neonatal Abstinence Syndrome. Tricia L. Romesberg, DNP, MSN, ARNP, CNNP
Clinical Management of Neonatal Abstinence Syndrome Tricia L. Romesberg, DNP, MSN, ARNP, CNNP Timeline Incidence of NAS Healthcare Cost and Utilization Project (HCUP), 1999-2013 State Inpatient Databases
More informationPinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu
Search for: Search Search Is tramadol the same as tylenol 3 Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu 29-3-2012 Hi, I have been on tramadol for pain relief since having cancer more
More information